Despite the firm again raising its revenue and GAAP guidance, we’ve made only minor changes to our model in the long run.

ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

AbbVie ABBV is set to report third-quarter earnings on Oct. 30, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.28 billion and $2.93 per share, ...

Migraine without aura is one of two major types of migraines, and 75% of those who have the condition experience this particular kind. Also known as "common" migraine, people who have migraine without ...

A screenshot of the ABC News-hosted presidential debate between Kamala Harris and Donald Trump in September 2024. Picture: Youtube screenshot of Wall Street Journal debate stream Half of the world ...

AbbVie sells another oral CGRP called Ubrelvy (ubrogepant) for acute treatment of migraine, which made around $552 million last year, and hasn't yet disclosed Qulipta's quarterly sales performance.

Please purchase a subscription to read our premium content. If you have a subscription, please log in or sign up for an account on our website to continue.

His accomplishments include spearheading successful patient marketing campaigns for notable pharmaceutical brands such as QULIPTA at AbbVie and UBRELVY, contributing significantly to their market ...

Just as more extreme weather swept over Norway's west coast last week, a new brochure was landing in Norwegians' mailboxes. It's part of further efforts to boost individual preparedness for various ...

This advertisement has not loaded yet, but your article continues below.